{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:27:19Z","timestamp":1772162839133,"version":"3.50.1"},"reference-count":17,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    A randomized, double-blind study comparing single-dose chlamydia therapies of oral rifalazil (25 mg) and azithromycin (1 g) was conducted in 82 women with uncomplicated genital\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Chlamydia trachomatis<\/jats:named-content>\n                    infection. The microbiologic cure rate of\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">C. trachomatis<\/jats:named-content>\n                    with rifalazil (\n                    <jats:italic>n<\/jats:italic>\n                    = 33) was 84.8% at the visit on day 22 to 26 (test-of-cure visit), versus 92.1% with azithromycin (\n                    <jats:italic>n<\/jats:italic>\n                    = 38), and the number of treatment failures in each group was 5 and 3, respectively. The difference in cure rate was \u22127.3%, with a lower limit of the 95% confidence interval (95% CI) of \u221222.5, and thus, noninferiority was not established at the prespecified margin (lower limit of CI of \u221215%). The overall treatment-emergent adverse event (TEAE) and treatment-related TEAE rates were lower in the rifalazil group (68% and 55%) than in the azithromycin group (71% and 62%), respectively. Subjects classified as treatment failures at day 22 to 26 had a lower mean plasma concentration of rifalazil at the visit on day 8 to 12 than those classified as treatment cures, but this difference was not significant; however, the levels were similar for both groups at the visit on day 22 to 26. A single 25-mg dose of rifalazil was well tolerated and eradicated\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">C. trachomatis<\/jats:named-content>\n                    in most of these women with uncomplicated genital\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">C. trachomatis<\/jats:named-content>\n                    infection. (The study was registered at clinicaltrials.gov under registration no. NCT01631201).\n                  <\/jats:p>","DOI":"10.1128\/aac.02521-14","type":"journal-article","created":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T23:36:16Z","timestamp":1399332976000},"page":"4014-4019","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["Randomized, Double-Blind, Multicenter Safety and Efficacy Study of Rifalazil Compared with Azithromycin for Treatment of Uncomplicated Genital Chlamydia trachomatis Infection in Women"],"prefix":"10.1128","volume":"58","author":[{"given":"William M.","family":"Geisler","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luz G.","family":"Pascual","sequence":"additional","affiliation":[{"name":"RFS Pharma, Tucker, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Mathew","sequence":"additional","affiliation":[{"name":"RFS Pharma, Tucker, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Koltun","sequence":"additional","affiliation":[{"name":"Medical Center for Clinical Research, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin","family":"Morgan","sequence":"additional","affiliation":[{"name":"Tidewater Physicians for Women, Norfolk, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron E.","family":"Batteiger","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Mayes","sequence":"additional","affiliation":[{"name":"Office of Annette Mayes, M.D., Las Vegas, Nevada, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijia","family":"Tao","sequence":"additional","affiliation":[{"name":"Center for AIDS Research, Emory University School of Medicine and Veterans Affairs Medical Center, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selwyn J.","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"Center for AIDS Research, Emory University School of Medicine and Veterans Affairs Medical Center, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chalom","family":"Sayada","sequence":"additional","affiliation":[{"name":"ActivBiotics Pharma, Tucker, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond F.","family":"Schinazi","sequence":"additional","affiliation":[{"name":"Center for AIDS Research, Emory University School of Medicine and Veterans Affairs Medical Center, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Sexually transmitted disease surveillance (reported in 2012)","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. 2011. Sexually transmitted disease surveillance (reported in 2012). CDC, U.S. Department of Health and Human Services, Atlanta, Georgia. http:\/\/www.cdc.gov\/std\/stats12\/Surv2012.pdf."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-001-0092-6"},{"issue":"12","key":"e_1_3_2_4_2","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2010","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","unstructured":"Centers for Disease Control and Prevention. 2010. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recommend. Rep. 59(RR-12):1\u2013116.","journal-title":"MMWR Recommend. Rep."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200209000-00001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/648734"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq074"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041681"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e3181a2a933"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182246a83"},{"key":"e_1_3_2_11_2","article-title":"Doryx (doxycycline hyclate delayed-release tablets)","author":"Warner Chilcott","year":"2013","unstructured":"Warner Chilcott. 2013. Doryx (doxycycline hyclate delayed-release tablets). Physician prescribing information. http:\/\/www.doryx.com\/pdf\/pi_doryx_tablet.pdf.","journal-title":"Physician prescribing information"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.200700080"},{"key":"e_1_3_2_13_2","first-page":"353","volume-title":"Assessment of antimicrobial resistance in Chlamydia trachomatis strains associated with treatment failure or same strain recurrence","author":"Stamm WE","year":"2002","unstructured":"StammWEGeislerWMSuchlandRJ. 2002. Assessment of antimicrobial resistance in Chlamydia trachomatis strains associated with treatment failure or same strain recurrence, p 353\u2013360. In Chlamydial infections: Proceeding of the 10th International Symposium on Human Chlamydial Infections, Antalya, Turkey."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1885-1886.2004"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.olq.0000253348.44308.8c"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.09.013"},{"key":"e_1_3_2_17_2","unstructured":"Pfizer. 2013. Zithromax (azithromycin) physician prescribing information. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=511."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007300745"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02521-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02521-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:47:11Z","timestamp":1645465631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02521-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1128\/AAC.02521-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.02521-14","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718376050.793501546","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"2014-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}